Abbotts Alinity aims to make comprehensive diagnostics systems

Many diagnostic testing machines are only compatible with products of the same brand, but Abbott hopes to change that with the introduction of its new family of Alinity products.

Alinity contains systems for the areas of immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. All of these products are in the same family of technology, making transferring information on multiple kinds of tests easier and eliminating human error.  

"With our unified family of testing instruments, we'll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care," said Brian Blaser, executive vice president-diagnostic products, Abbott.

The systems work together to offer a greater capacity and simpler care for patients. Most of the new family of systems are able to run multiple tests at once and in less space, further showing the innovation and increase in quality of Alinity.

"Abbott's Alinity systems are being built from the ground up based on customer insights, using the latest technologies suitable for testing today and in the future," said Dennis Gilbert, PhD, vice president, research and development-diagnostic products, Abbott. "Whether it's an easy-to-use software interface, running more tests faster or the ability to run any test at any time, our Alinity platforms are designed to include these features and more without any compromise in performance or quality."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year.